ArticleBMC gastroenterology2026
Cancer antigen 125 levels change rule after laparoscopic biopsy and its prognostic value for patients with unresectable pancreatic ductal adenocarcinoma: a retrospective preliminary exploratory study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPrecise staging is essential for treatment options and patient benefits in individuals with unresectable pancreatic ductal adenocarcinoma (PDAC). Laparoscopic biopsy is a minimally invasive procedure used to identify radiographically occult metastases and accurately stage unresectable PDAC. The cancer antigen 125 (CA125) levels change rule after laparoscopic biopsy and its correlation with overall survival (OS) in patients with unresectable PDAC remains unclear.
methodsWe analyzed electronic medical records and follow-up data of patients diagnosed with unresectable PDAC by laparoscopic biopsy. Dynamic measurement of CA125 levels was used to analyze the CA125 levels change rule after laparoscopic biopsy and its prognostic significance.
resultsA total of 123 patients were ultimately included in our study, categorized into the unresectable locally advanced (UR-LA) and unresectable metastasis (UR-M) groups. In the UR-M group, CA125 levels were significantly elevated at 2 weeks after the first chemotherapy compared to preoperative levels. These elevated levels did not correlate with poor OS. Although CA125 levels decreased significantly at 4 weeks after the first chemotherapy, the values ≥ 35 U/mL were correlated with poor OS. A similar CA125 levels change rule was observed in the UR-LA group, but CA125 levels had no prognostic value at each time point. In patients with UR-M PDAC, a drop in CA125 levels below 35 U/mL within 4 weeks after the first chemotherapy was associated with better OS, regardless of whether the values exceeded 35 U/mL in the early postoperative period.
conclusionsThe CA125 levels change rule after laparoscopic biopsy can be used to predict the prognosis of patients with unresectable metastatic PDAC. CA125 levels remaining above 35 U/ml for longer than 4 weeks after the first chemotherapy is associated with a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.